More research into CNTF treatment required

Article

According to a study published in Investigative Ophthalmology and Visual Science more research into the effect of sustained-release ciliary neurotrophic factor (CNTF) treatment, on patients with inherited retinal degenerations, using high-resolution imaging techniques is required.

According to a study published in Investigative Ophthalmology and Visual Science more research into the effect of sustained-release ciliary neurotrophic factor (CNTF) treatment, on patients with inherited retinal degenerations, using high-resolution imaging techniques is required.

Dr Jacque L. Duncan from the Beckman Vision Center, School of Medicine, University of California, San Francisco, California, USA, led a study group in the examination of the cone photoreceptor structure and function of the 2 patients with retinitis pigmentosa and 1 patient with usher syndrome.

All patients participated in a phase II clinical trial and were treated with sustained-release CNTF delivered by an encapsulated cell technology implant in one eye and sham surgery in the other. The outcome measures were obtained using AOSLO.

The results show that outer retinal layers were significantly thicker in CNTF treated eyes than the sham-treated eyes. The findings demonstrated there were no significant changes in VA, visual field sensitivity or ERG responses. AOSLO is a sensitive way to measure disease progression and reactions to treatment in patients. A larger study is required to determine the effect of CNTF treatment in inherited retinal degenerations.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.